Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer

Executive Summary

Pfizer got Bavencio to market by focusing on an unmet need, but the PD-L1 inhibitor is still a few years behind, competing with other checkpoint inhibitors over more valuable indications.

Advertisement

Related Content

Keeping Track Of The US FDA's Final Approvals Of 2018
Merck KGAA/Pfizer's Anti-PD-L1 Bavencio Loses An Opportunity In Ovarian Cancer
Deal Watch: Pfizer Offloads Troubled ADHD Products To Manufacturer Tris
Pfizer/Merck KgAA Move Fast With Bid For Bavencio/Inlyta In Kidney Cancer Market
Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala
First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo
Pfizer/Merck KGAA's Bavencio Fails OS Endpoint In Second-Line Lung Cancer
Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems
Pfizer Takes Step Back With Avelumab, Step Forward On CAR-T
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098447

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel